ANGPTL3 and familial hyperaldosteronism: Eventually, only studies in homozygous FH patients treated with ANGPTL3 inhibitor may be able to provide definitive answers, given that the EL-mediated pathway we discovered in mice only becomes critical in the absence of functional LDLR.